Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14(2):135–146

CAS  PubMed  Google Scholar 

Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, B-vdM DM et al (2008) Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 14(1):178–187

CAS  PubMed  Google Scholar 

Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, B-vdM DM, Vloon AP et al (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361(19):1838–1847

CAS  PubMed  Google Scholar 

Andersen MH, Fensterle J, Ugurel S, Reker S, Houben R, Guldberg P et al (2004) Immunogenicity of constitutively active V599EBRaf. Cancer Res 64(15):5456–5460

CAS  PubMed  Google Scholar 

Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G (1997) Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer 72(5):784–790

CAS  PubMed  Google Scholar 

Linard B, Bezieau S, Benlalam H, Labarriere N, Guilloux Y, Diez E et al (2002) A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol 168(9):4802–4808

CAS  PubMed  Google Scholar 

Ito D, Visus C, Hoffmann TK, Balz V, Bier H, Appella E et al (2007) Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck. Int J Cancer 120(12):2618–2624

CAS  PubMed  Google Scholar 

Holmstrom MO, Hjortso MD, Ahmad SM, Met O, Martinenaite E, Riley C et al (2017) The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms. Leukemia 31(2):495–498

CAS  PubMed  Google Scholar 

Holmstrom MO, Riley CH, Svane IM, Hasselbalch HC, Andersen MH (2016) The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. Leukemia 30(12):2413–2416

CAS  PubMed  Google Scholar 

Holmstrom MO, Martinenaite E, Ahmad SM, Met O, Friese C, Kjaer L et al (2017) The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia 10

Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP et al (1998) Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 101(10):2290–2296

CAS  PubMed  PubMed Central  Google Scholar 

Yotnda P, Garcia F, Peuchmaur M, Grandchamp B, Duval M, Lemonnier F et al (1998) Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest 102(2):455–462

CAS  PubMed  PubMed Central  Google Scholar 

Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ et al (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482(7385):400–404

CAS  PubMed  PubMed Central  Google Scholar 

Balachandran VP, Luksza M, Zhao JN, Makarov V, Moral JA, Remark R et al (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551(7681):512–516

CAS  PubMed  PubMed Central  Google Scholar 

Gjerstorff MF, Andersen MH, Ditzel HJ (2015) Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget 6(18):15772–15787

PubMed  PubMed Central  Google Scholar 

Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E et al (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921–930

CAS  PubMed  Google Scholar 

Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P et al (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2(2):167–175

CAS  PubMed  Google Scholar 

De BO, Arden KC, Boretti M, Vantomme V, De SC, Czekay S et al (1999) Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res 59(13):3157–3165

Google Scholar 

Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z et al (2013) Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36(2):133–151

CAS  PubMed  PubMed Central  Google Scholar 

Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethe B et al (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489–495

CAS  PubMed  Google Scholar 

Kawakami Y, Rosenberg SA (1997) Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int Rev Immunol 14(2-3):173–192

CAS  PubMed  Google Scholar 

Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y (1998) Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 58(21):4895–4901

CAS  PubMed  Google Scholar 

Heiser A, Dahm P, Yancey DR, Maurice MA, Boczkowski D, Nair SK et al (2000) Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 164(10):5508–5514

CAS  PubMed  Google Scholar 

Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML et al (2010) HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother 59(6):943–953

CAS  PubMed  PubMed Central  Google Scholar 

Andersen MH, Becker JC, Straten P (2005) Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 4(5):399–409

CAS  PubMed  Google Scholar 

Andersen MH, Pedersen LO, Becker JC, thor Straten P (2001) Identification of a Cytotoxic T Lymphocyte Response to the Apoptose Inhibitor Protein Survivin in Cancer Patients. Cancer Res 61:869–872

CAS  PubMed  Google Scholar 

Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, Thor Straten P (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61(16):5964–5968

CAS  PubMed  Google Scholar 

Andersen MH, Reker S, Becker JC, Thor Straten P (2004) The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. J Invest Dermatol 122(2):392–399

CAS  PubMed  Google Scholar 

Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S et al (2005) Immunogenicity of Bcl-2 in cancer patients. Blood 15(105(2)):728–734

Google Scholar 

Andersen MH, Becker JC, thor Straten P (2005) The anti-apoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients. Leukemia 19(3):484–485

CAS  PubMed  Google Scholar 

Andersen MH, Reker S, Kvistborg P, Becker JC, thor Straten P (2005) Spontaneous immunity against Bcl-X(L) in cancer patients. J Immunol 175(4):2709–2714

CAS  PubMed  Google Scholar 

Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10(6):673–679

CAS  PubMed  Google Scholar 

Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H et al (1999) Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163(2):1037–1044

CAS  PubMed  Google Scholar 

Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H et al (2003) Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int J Hematol 78(1):56–61

CAS  PubMed  Google Scholar 

Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al (2004) Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101(38):13885–13890

CAS  PubMed  PubMed Central  Google Scholar 

Kjeldsen JW, Lorentzen CL, Martinenaite E, Ellebaek E, Donia M, Holmstroem RB et al (2021) A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med 27(12):2212–2223

CAS  PubMed  PubMed Central  Google Scholar 

Andersen MH (2018) The Balance Players of the Adaptive Immune System. Cancer Res 78(6):1379–1382

CAS  PubMed  Google Scholar 

Andersen MH (2015) Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. J Natl Cancer Inst 107(9):154

Google Scholar 

Andersen MH (2017) Anti-regulatory T cells. Semin Immunopathol 39(3):317–326

CAS  PubMed  Google Scholar 

Sorensen RB, Hadrup SR, Svane IM, Hjortso MC, Thor Straten P, Andersen MH (2011) Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 117(7):2200–2210

PubMed  PubMed Central  Google Scholar 

Sorensen RB, Kollgaard T, Andersen RS, van den Berg JH, Svane IM, Thor Straten P et al (2011) Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res 71(6):2038–2044

CAS  PubMed  Google Scholar 

Hjortso MC, Larsen SK, Kongsted P, Met O, Frosig TM, Andersen GH et al (2015) Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. Oncoimmunology 4(1):e968480

PubMed  PubMed Central  Google Scholar 

Ahmad SM, Larsen SK, Svane IM, Andersen MH (2014) Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia 28(1):23